ENZN — trading under the old Enzon Pharmaceuticals ticker but now the OTC vehicle for Viskase Holdings, Inc. — enters the final days of April with borrow costs running at their highest level in over a year and a flurry of regulatory filings raising fresh questions about where the company is headed.
The borrowing cost story is the standout this week. The cost to borrow has more than doubled over the past month, climbing from around 6.5% to nearly 15% annualised — a level not seen in the data going back through most of 2024. The move has been persistent rather than spiky: CTB has risen in almost every reading since late January, when it was below 0.5%. That kind of steady, multi-month grind higher in borrowing costs usually reflects a structural shift in demand for the stock, not a one-day technical glitch. Yet availability in the lending pool remains extremely wide at roughly 8,596% of estimated short interest — meaning there is vastly more stock available to borrow than is actually being borrowed. The two signals sit in tension: borrow is getting pricier, but the pool is far from exhausted.
Short interest itself is negligible as a directional signal. Estimated SI is a fraction of a percent of the free float — fewer than 6,000 shares short against a company with over 14 million shares outstanding, per the FINRA fortnightly filing showing just 249 shares as of April 15. The month-on-month percentage change looks dramatic in the data, but that reflects a near-zero base in early April rather than meaningful short conviction. The ORTEX short score sits at 40.4, modestly below mid-range, consistent with the absence of real short pressure. Options data is stale to the point of being unusable — the most recent PCR reading is from August 2016, so that angle is closed entirely.
The institutional picture is the most consequential factor on this name. Carl Icahn's vehicle, Icahn Capital LP, controls an extraordinary 93.7% of the company — a stake that increased by over 13.3 million shares in the most recent filing dated March 26. With a single activist holding that proportion of shares, float is effectively negligible, which explains both the thinness of the borrow market and the subdued short activity. Thomas Davis also added 16,678 shares in the same filing period, a small but new position among the registered holders.
The regulatory filings this month add context to the price action. Viskase filed an 8-K on April 16 disclosing a change in its certifying accountant, followed by another 8-K on April 21 announcing entry into a material definitive agreement — neither filing was accompanied by an explanatory press release visible in the public news feed. The company also filed a 10-K/A amendment on April 29, just one day before this note. The stock fell 13.6% over the week to $5.90, a significant move for a thinly traded OTC name, and the combination of the auditor change, the undisclosed agreement, and the annual filing amendment compressed into a ten-day window is an unusual cluster of disclosure activity.
Earnings history offers a mixed picture. The most recent announced event, in early March, produced a 4% one-day gain but the stock then fell 17% over the following five sessions. The November 2025 print was far more dramatic — a 54% single-day spike followed by a 42% five-day gain — suggesting the stock can move violently on catalysts, in either direction, with Icahn's concentrated ownership amplifying any float-driven move. No next earnings event is scheduled in the data.
The week ahead centres less on short interest mechanics and more on what Viskase's April 21 material definitive agreement actually involves — that disclosure, when it arrives in full, is the single datapoint most likely to drive the next leg in this name.
See the live data behind this article on ORTEX.
Open ENZN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
